Navigation Links
New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T
Date:11/7/2011

nt fever, bruising, bleeding, pallor) while on CIMZIA. Consider discontinuation of CIMZIA therapy in patients with confirmed significant hematologic abnormalities.

Drug Interactions

An increased risk of serious infections has been seen in clinical trials of other TNF blocking agents used in combination with anakinra or abatacept.  Formal drug interaction studies have not been performed with rituximab or natalizumab; however because of the nature of the adverse events seen with these combinations with TNF blocker therapy, similar toxicities may also result from the use of CIMZIA in these combinations.  Therefore, the combination of CIMZIA with anakinra, abatcept, rituximab, or natalizumab is not recommended.  Interference with certain coagulation assays has been detected in patients treated with CIMZIA. There is no evidence that CIMZIA therapy has an effect on in vivo coagulation. CIMZIA may cause erroneously elevated aPTT assay results in patients without coagulation abnormalities.

Autoimmunity

Treatment with CIMZIA may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome. Discontinue treatment if symptoms of lupus-like syndrome develop.

Immunizations

Do not administer live vaccines or attenuated vaccines concurrently with CIMZIA.

Adverse Reactions

In controlled Crohn's clinical trials, the most common adverse events that occurred in greater than or equal to 5% of CIMZIA patients (n=620) and more frequently than with placebo (n=614) were upper respiratory infection (20% CIMZIA, 13% placebo), urinary tract infection (7% CIMZIA, 6% placebo), and arthralgia (6% CIMZIA, 4% placebo). The proportion of patients who discontinued treatment due to adverse reactions in the controlled clinical studies was 8% for CIMZIA and 7% for placeb
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015 Amgen (NASDAQ: AMGN ) today ... Key results include: , Total revenues increased 11 ... million, with 12 percent product sales growth driven primarily ... EPOGEN ® (epoetin alfa), Sensipar ® (cinacalcet) ... exchange rates impacted total revenue and product sales growth ...
(Date:4/21/2015)... 2015  Inmark,s acquisition of Saf-T-Pak last week ... Training, specifically Division 6.2.  For over 25 years, ... programs focusing on IATA, ICAO, US DOT, Transport ... "We were particularly interested in Saf-T-Pak,s proprietary ... internet training programs," said David Oyler , ...
(Date:4/21/2015)... , April 21, 2015 The global dermatology ... CAGR of 8.2% from 2014 to 2019. ... hold larger shares in the global dermatology diagnostic ... devices market is mainly attributed to a wide range ... growing demand of dermatologists, and technological advancements made in ...
Breaking Medicine Technology:Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 2Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 3Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 4Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 5Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 6Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 7Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 8Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 9Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 10Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 11Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 12Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 13Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 14Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 15Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 16Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 17Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 18Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 19Inmark's Acquisition Of Saf-T-Pak Results In Expansion Of Its Dangerous Goods Training Portfolio 2Dermatology Diagnostic Devices Market by Product, by End-User - Global Forecast to 2019 2Dermatology Diagnostic Devices Market by Product, by End-User - Global Forecast to 2019 3
... MELVILLE, N.Y. , July 19 Nycomed US Inc. today ... Executive Officer. He assumes immediate responsibility for Nycomed US Inc., including manufacturing ... commercial operations for the three marketing and sales divisions Fougera, PharmaDerm and ... , ...
... announces that a new market research report is available in its catalogue: , ... Global Pharma-biotech Alliance Analysis , ... , , , ... deals struck from 2008 to present. This study covers deal structures by therapeutic area, stage ...
Cached Medicine Technology:Steve Andrzejewski Joins Nycomed US Inc. 2Reportlinker Adds Global Pharma-biotech Alliance Analysis 2
(Date:4/21/2015)... (PRWEB) April 21, 2015 The Alzheimer’s ... partnership with JustSayCheese.com, a Colorado business that turns personal ... According to Larry Barrett, Vice President of Sales for ... in the fact that many of us have personal ... dedicated to working hard to support the Association’s efforts. ...
(Date:4/21/2015)... 21, 2015 Grafika is pleased to ... Offset Impressions. , “We’re excited about the ... printing capabilities and knowledgeable team members,” according to Bernard ... us to offer an ever wider breadth of products ... and specialty services we already offer. It also ...
(Date:4/21/2015)... “ ZeroWire ” was featured on ... takes a look at the latest and coolest technology ... special reporter for NewsWatch and a technology expert, conducted ... a security system and lifestyle management hub. , According ... 2 million burglaries in 2010. It goes without saying ...
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 21, 2015 ... Review, H1 2015” provides comparative analysis on ... strengthens R&D pipelines by identifying new targets ... products. Complete report with TOC is available ... report also reviews key players involved in ...
(Date:4/21/2015)... AvePoint, the established leader in ... a new enhancement to DocAve Policy Enforcer ... Management Activity API. This integration creates a new information ... action on all events that take place throughout their ... Activity API provides customers with greater transparency and insight ...
Breaking Medicine News(10 mins):Health News:A Leader in Home Security was Featured on NewsWatch Television 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 2Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 3
... Using insect repellent in addition to insecticide treated bednets (ITNs) ... areas where mosquitoes feed in the early evening. , The ... at the London School of Hygiene & Tropical Medicine and ... at the Ministry of Health in La Paz, Bolivia, are ...
... Nov. 12 What does a,thirty-nine foot Airstream Land ... For more than 800 midlands, men last month, it ... for the disease. The Drive Against Prostate Cancer ... prostate cancer. Doctors Care and WIS-TV,sponsored The Drive in ...
... China Pharma,Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI) ... at 11:00 a.m. EST on Thursday,November, 15, 2007, to ... Joining Ms. Zhilin Li, President and CEO of China ... Company plans to release its,earnings earlier that same day. ...
... Nov. 12 SpaCapsule(R),( http://www.spacapsule.com ), the most advanced ... one sleek, space-age,machine, has retained one of Florida,s ... quickest de-stressing and relaxation experience on,the planet. ... machine that in a matter,of minutes can take ...
... Rose 12.8% to US$14.3 Million (RMB 107.7 ... Million) Compared to Third Quarter 2006, BEIJING, ... FFHL ), a manufacturer and distributor of,high-quality BOPET plastic film ... quarter and for the nine months,ended September 30, 2007 which ...
... Global Landmarks Mark First United Nations World Diabetes Day ... up in blue to mark the,first United Nations-observed World ... most iconic buildings and sites. The landmarks will,light up ... circle, the global,symbol for diabetes. The Empire State ...
Cached Medicine News:Health News:Repellents between dusk and bedtime make insecticide-treated bednets more effective 2Health News:UCI Medical Affiliates, Inc. Sponsors Doctors Care Record-breaking Drive Against Prostate Cancer 2Health News:China Pharma Holdings, Inc. Announces Conference Call to Discuss Third Quarter 2007 Results 2Health News:The Ultimate Stress Reliever, SpaCapsule(R), the Capsule that Takes You on a Rejuvenating Journey to the Spa, Retains TransMedia Group for Soothing PR 2Health News:Fuwei Films Announces Third Quarter 2007 Financial Results 2Health News:Fuwei Films Announces Third Quarter 2007 Financial Results 3Health News:Fuwei Films Announces Third Quarter 2007 Financial Results 4Health News:Fuwei Films Announces Third Quarter 2007 Financial Results 5Health News:Fuwei Films Announces Third Quarter 2007 Financial Results 6Health News:World Diabetes Day Lights Up the Skyline 2Health News:World Diabetes Day Lights Up the Skyline 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: